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Summory
In this paper we present anew method for the detection ofresistance
to activated protein C (APC) that is based on direct measurement of the
effect of APC on the cofactor activity of plasma factor Va. The factor V
present in a diluted plasma sample was activated with thrombin and its
sensitivity towards APC was subsequently determined by incubation
with phospholipids and APC. The loss of factor Va cofactor activity
was quantified in a prothrombinase ystem containing purified pro-
thrombin, factor Xa and phospholipid vesicles and using a chromogen-
ic assay for quantitation of thrombin formation. The reaction conditions
were optimized in order to distinguish normal, heterozygous and ho-
mozygous APC-resistant plasmas. Maximal differences in the response
of these plasmas towards APC were observed when factor Va was inac-
tivated by APC in the absence of protein S and when the cofactor activ-
ity of factor Va was determined at a low factor Xa concentration
(0.3 nM).
Addition of 0.2 nM APC and 20 pM phospholipid vesicles to a
1000-fold iluted sample of thrombin-activated normal plasma resulted
in loss of more than 8570 of the cofactor activity factor Va within
6 min. Under the same conditions, APC inactivated -6070 and -20% of
the factor Va present in plasma samples from APC-resistant i dividuals
that were heterozygous or homozygous for the mutation Arg506-+Gln in
factor V, respectively. Discrimination between the plasma samples
from normal and heterozygous and homozygous APC-resistant i divid-
uals was facilitated by introduction of the so-called APC-sensitivity
ratio (APC-sr). The APC-sr was defined as the ratio of the factor Va co-
factor activities determined in thrombin-activated plasma samples after
6 min incubation with or without 0.2 nM APC and was multiplied by
100 to obtain integers (APC-sr = {factor Va*o../factor Va-*.J x 100).
Clear differences were observed between the APC-sr of plasmas from
normal healthy volunteers (APC-sr: 8-20, n = 33) and from individuals
that were heterozygous (APC-sr: 35-50, n = 17) or homozygous APC
resistant (APC-sr: 82-88, n = 7). There was no mutual overlap between
the APC-sr of normal plasmas and plasmas from heterozygous or ho-
mozygous APC resistant individuals (p <0.0001). In all cases our test
gave the same result as the DNA-based assay. Since the test is per-
formed on a highly diluted plasma sample there is no interference by
conditions that affect APC resistance t sts that are based on clotting
time determinations (e. g. coagulation factor deficiencies, oral anticoag-
ulation, heparin treatment, the presence of lupus anticoagulants, preg-
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nancy or the use of oral contraceptives). Furlhermore, we show that part
of the factor Va assay can be performed on an autoanalyzer which in-
creases the number of plasma samples that can be handled simultane-
ously.
Infroduction
In 1993, Dahlbiick et al. (1) described a hereditary defect in the anti-
coagulant response to activated protein C (APC) that is associated with
an increased risk for venous thrombosis. This abnormality, called APC
resistance, was subsequently identified as the most common defect in
thromboembolic patients (2-6) and was found in 20-5070 of patients
with venous thrombosis. APC resisiance is associated with familial
thrombophilia and is inherited as an autosomal dominant trait. The mo-
lecular defect responsible for APC resistance isa single point mutation
in the gene encoding for coagulation factor V. This mutation results in
the substitution of Args06 by Gln in the heavy chain domain of factor
V(a) (7-11). Since fug506 constitutes one of three APC cleavage sites in
factor Va (12), the mutated factor V(a), also described ut fu.1s1 yldden
or factor VR506Q, is much less effectively inactivated by APC than
normal factor Va (13, 14). Since APC-catalyzed inactivation of factor
Va is a crucial step in the down-regulation f thrombin formation this
likely explains the increased risk for venous thromboembolism in indi-
viduals with APC-resistant plasma.
The requirement for reliable detection of APC resistance became im-
portant when it was discovered that at least 2 to 4Vo of the Caucasian
population isAPC-resistant (2,3,6,1). Several methods for the diagno-
sis of APC resistance have been described so far (15). Most of these
methods are based 0n sequence analysis of genomic DNA (7, 16) or on
measurement of the effect of APC on the activated partial thromboplas-
tin time (APTT) (1, 17, 18) or on thrombin generation i  plasma (19).
APTT-based APC-resistance assays appear to be less reliable in the
case of other coagulation disorders (11,20-22), anticoagulant therapy
(2,4,6,23), pregnancy (21) or the use of oral contraceptives (24,25).
In this paper, we repofi a different method for the identification of
APC-resistant plasmas. The method is based on direct measurement of
the effect of APC on the activity of factor Va in diluted thrombin-acti-
vated plasma samples and subsequeni determination of factor Va cofac-
tor activity in prothrombin activation.
Moleriols ond Methods
Materials and Buffers
The phospholipids 1,2-dioleoyl-sn-glycero-3-phosphoserine (DOPS) and
1,2-dio1eoy1-sn-glycero-3-phosphocholine (DOPC) w re obtained from Avanti
Polar Lipids, Alabaster, Alabama, USA. The chromogenic substrates D-Phe-
(pipecolyl)-Arg-pNA (S2238) and L-pyroGlu-Pro-Arg-pNA (S2366) were sup-
plied by Chromogenix, Mti1ndal, Sweden. Recombinant human APC (rAPC)
was a kind gift of Immuno AG, Vienna, Austria. Human protein S was
purchased from Enzyme Research Laboratories, Swansea' United Kingdom'
Human protluombin and human factor X were purified as described by DiSci-
pio et al. (26) Human factor X was converted into factor Xa by incubation with
the purified factor X activator from Russel's viper venom and factor Xa was
isolated from the activation mixture by cluomatography on soybean trypsin in-
hibitor-Sepharose (27).
A11 proteins used in the APC resistance t st were diluted in buffer I (25 mM
Hepes [pH ?.5], 175 mM NaCl, 3 mM CaCl, and 5 mg/ml BSA).
Ph osphol ipid V e sic le P reparat ions
Small unilamellar phospholipid vesicles composed of a mixture of DOPS/
DOPC (10/90, M/l\4) were prepared as described earlier (28). Phospholipid
concentrations were determined by phosphate analysis (29).
P r ote in C onc entrati ons
APC concentrations were determined with 52366 using kinetic parameters
reported by Sala et al (30). Thrombin concentrations were determined with the
chromogenic substrate 52238 (31). Protein S concentrations were calculated
from the Arro using an A17"rro of 9.5 and Mr = 70,000 for protein S (32) Factor
V and factor Va concentrations were determined by measuring their activity in
prothrombin activation (14, 33) under conditions described in the legends to the
figures.
Collection and Handling of Plasma Samples
Nine parts of blood from normal heaithy volunteers or from individuals
(both men and women) that were shown to be heterozygous orhomozygous for
the Arg506+G1n mutation in factor V by DNA analysis (34) were collected in
one part of 0.13 M trisodium citrate (pH 7 8). The blood was centrifuged twice
for 15 minutes at 3,000 X g at room temperature The platelet poor plasma thus
obtained was stored at -80' C. The healthy volunteers had a normal APTT and
prothrombin time, a normal response to APC and DNA anaiysis howed that
they were not canying the Arg506-+Gln mutation. A normal plasma pool was
obtained by mixing the plasma of 84 different healthy volunteers (both men and
women). Coagulation factor concentrations (including protein S and C) of all
volunteers were within the normal range.
Chr omo g enic AP C' r e s i s tanc e T e st
The procedure that we have developed basically consists of three steps that
are performed aI3'7" C: 1) activation of plasma factor V with thrombin, 2) in-
cubation of factor Va with or without APC and 3) quantification of factor Va
cofactor activity.
Step 1: To two tubes (samples A and B) with 215 pl of 1/1000 dilutions of
the same plasma sample in buffer I, 5 pl of a mixture of 175 nM thrombin and
I mM phospholipid vesicles (10/90 MA4 DOPS/DOPC) were added to activate
the factor V present in the plasma sample.
Step 2: After 10 min i0 p1 buffer I was added to sample A and 10 pl puri-
fied rAPC (4 6 nM) was added to sample B and the incubation at 37o C was
continued.
Step 3: After 6 min incubation with APC, 10 pl prothrombin (25 pM) and
10 u,l factor Xa (7.5 nM) were added to the samples A and B in order to deter-
mine the factor Va cofactor activity present. After 1 min, the amount of throm-
bin generated in the reaction aliquots was quantitated by transfening a10 pl al-
iquot into a disposable cuvette with 990 p1 of a buffer containing 235 p'M 52238
in 50 mM Tris (pH'7.5 at3'7'C), 175 mM NaCl,0.5 mg/ml ovalbumin and
20 mM EDTA. The factor Va concentration i  the plasma sample was calculat-
ed from the thrombin formed using a calibration curve made with known
amounts of purified factor Va (34)
The final concentrations of essential reaction components in the different
steps were: step 1) 1/1000 dilution of plasma sample, 4 nM thrombin and
22.7 pM DOPS/DOPC (i0/90, MA4) vesicies; step 2),02 nM APC and
21.7 pM DOPS/DOPC (10/90) vesicles; tep 3) 0.25 pM prothrombin, 0 3 nM
factor Xa and 20 pM DOPS,DOPC (10/90) vesicles.
The factor Va assay procedure (step 3) is essentially the same as reported
earlier (33) However, in this particular application factor Va was assayed at
0.3 nM factor Xa since at this factor Xa concentration the residual cofactor
activity of the reaction intermediate cleaved at Argso0 tt negligible compared
to native factor Va (14). This increased the difference in response between
normal and factor VaR506Q in the test (see Results). Plasma samples were
assayed within t h of thawing, although samples, kept at room temperature for
20 h, could be assayed without loss of assay accuracy. The inffa-assay variation
of the test was Jl6 (n = l7), the inter-assay variation is 47o (n = 20).
Semi-automated Method for the Detection of APC Resistance
Plasma samples were diluted 750 times in a 25 mM Hepes buffer (pH 7'5)'
containing 175 mM NaCl, 5 mM CaCl, and 5 mg/ml BSA, (buffer II)' After
prewarming two aliquots of 400 p1 of the same plasma sample at 37" C, 16 pl
of a mixture of 67 nM thrombin and 667 pM phospholipids (10/90 DOPS/
DOPC MA4) without (sample A) or with 10 nM APC (sample B) was added
yielding final concentrations of 4 nM thrombin, 20 pM phospholipid vesicles
with or without 0.39 nM APC, respectively. After 20 min incubation' i e' acti-
vation of plasma factor V (sample A) or activation and inactivation of plasma
factor V (sample B) the reaction was stopped by the addition of 4500 pl cold
buffer I (4" C). After dilution of the APC-treated plasma sample APC-catalyzed
factor Va inactivation at 37o C is slowed down -100-fold and becomes consid-
erably slower than the rate of spontaneous loss of factor va cofactor activity
(<0.3 Talmin at 37" C). Since spontaneous loss of factor Va activity occurs both
in non-treated and APC{reated plasma samples any loss of factor Va activity
during the preincubation/incubation procedure in the ACL-300 will not affect
the APC-sr.
The cofactor activity of factor Va present in the plasma samples was deter-
mined on an ACL-300 Research Automated Coagulation apparatus (Instrumen-
tation Laboratory, Milan, Italy). Protluombin activation was started by mixing
50 pl aliquots of the plasma dilutions with 50 p.l 2 pM prothrombin, 0 6 nM
factor Xa and 40 pM phospholipids (10/90 DOPS/DOPC MA4) in 25 mM
Hepes (pH 7.5), 175 mM NaCl. After 2 min prothrombin activation was
stopped by mixing with 50 pl of 60 mM EDTA in 25 mM Hepes (pH 7'5),
175 mM NaC1, 0.5 mg/ml ovalbumin and 2.35 mM 52238 and the thrombin
present was assayed by monitoring 52238 conversion for 1 min at 405 nm'
Under the conditions described above 52238 conversion appeared tobe propor-
tional with the amount of factor Va present in the plasma sample'
Statistics
Data are presented as ranges of values observed, median values or as mean
1 S.E M. The Student's t-test was used to determine the significance of differ-
ences between test results of groups of plasmas.
Resulls
APC-mediated Inactivation of Factor Va Generated
in Normal-pooled Plasma nd in Plasmas from Heterozygous
and Homozy gous AP C' r e sistant Individuals
The chromogenic method [o screen plasmas for APC resistance is
actually based on earlier publications from our group conceming asen-
sitive assay for factor Va (33), kinetic analysis of APC-catalyzed inac-
tivation of factor Va and factor VaR506Q (14) and the effects of protein S
and factor Xa thereon (35)
Recently, we have shown (14) that APC inactivates normal factor
Va 20 times faster than factor VaR506Q. The difference between the
observed rates of inactivation of factor Va and factor VaR506Q was
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Flg. 1 Effect of APC on the activity of factor Va generated in normal plasma
and in plasma from heterozygote and homozygote APC-resistant individuals.
Normal-pooled plasma (I), plasma from heterozygous (O) or homozygous
(A) APC-resistant individual was diluted 1000 times in buffer I and factor V
was activated at 37" C with 4 nM thrombin the presence ofphospholipid ves-
icles (10/90 DOPS/DOPC M/l\4) After 10 min APC with or without protein S
was added to inactivate factor Va. The formation and loss of factor Va cofactor
activity was followed as described in "Materials and Methods" For each pias-
ma sample the factor Va activity is given as Va of its plateau value Time
courses offactor V activation i  the different plasmas and the spontaneous loss
of factor Va activity were indistinguishable andare therefore given in the
figure as a single averaged curve (O) for the ttiree different plasmas. The final
concentrations f components during the inactivation and assay procedures
were: A) 0.2 nM APC and21;7 pM phospholipid vesicles during inactivation
and 0.3 nM factor Xa, 1 pM prothrombin a d 20 pM phospholipid vesicles in
the factor Va assay mixture; B) 0.2 nM APC, 200 nM protein S and 21.7 pM
phospholipid vesicles during inactivation and 0 3 nM factor Xa, I pM
prothrombin a d 20 pM phospholipid vesicles inthe factor Va assay mixture
and C) 0.2 nM APC and2l.7 pM phospholipid vesicles during inactivation a d
10 nM factor Xa, 1 pM prothrombin a d 20 pM phospholipid vesicles in the
factor Va assay mixture
maximal when the loss of cofactor activity of factor Va was monitored
in protluombin activation mixtures that contained alow factor Xa con-
centration (e. g. 0.3 nM, cf. ref. 14). Furlhermore, we reported that dif-
ferences in the rates of inactivation of factor Va and factor VaR506Q were
less pronounced oreven nullified when factor Va was inactivated in the
presence of protein S and/or factor Xa (35).
Since the plasma ofnormal healthy volunteers contains - 25 nM fac-
tor V (36) and since our factor Va assay allows quantitation offactor Va
as iow as 0.2 pM it is possible to determine the sensitivity of plasma
factor Va towards APC at high plasma dilutions (>1000-fo1d), indepen-
dent from and unaffected by other plasma components. The procedure
that we have developed for distinguishing normal and APC-resistant
plasmas basically consists of three steps: 1) activation of the factor V
present in a highly diluted plasma sample with thrombin, 2) incubation
of factor Va in the presence of phospholipids with or without APC and
3) quantification of factor Va cofactor activity. In order to obtain opti-
mal differentiation between plasmas from notmal healthy individuals,
heterozygous and homozygous APC individuals the inactivation of fac-
tor Va should theoretically be performed in the absence of factor Xa
and protein S (35) and the cofactor activity of factor Va should be as-
sayed at a low factor Xa concentration (14).
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Fig. 1A shows that under these conditions the factor Va formed by
thrombin in a normal plasma sample was indeed readily inactivated by
0.2 nM APC whereas the factor Va present in the plasma sample from
a heterozygous APC-resistant patient showed intermediate sensitivity
and that in plasma from a homozygous APC-resistant patient was very
slowly inactivated by APC. The differences in response towards APC
were much less pronounced when protein S was present during factor
Va inactivation (Fig. lB) or when the loss of cofactor activity of factor
Va was assessed in a prothrombinase mixture that contained a high con-
centration of factor Xa (Fig. lC).
For practical reasons it is preferable that an APC-resistance test is
based on measurement of sensitivity of plasma factor Va towards APC
at a single time point. Quantitative comparison of the plasma samples
was facilitated by expressing their response towards APC in terms of
the so-called APC sensitivity ratio (APC-sr, cf.ref.2,11, 17-18). The
APC-sr is defined as the ratio of the factor Va activities determined af-
ter incubation of the plasma factor Va in the presence and absence of
APC and was multiplied by 100 to obtain integers (APC-sr = ffactor
Va**./factor Va-Apc] x 100). It appeared that under the reaction con-
ditions of the experiment presented in Fig. 1A, clear differences
between the APC-sr of the various plasmas were obtained for incuba-
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tion times between 2 and 15 min. Therefore, in the case of a single time
point assay, we have arbitrarily chosen for determination of the APC-sr
after 6 min incubation with APC. Under these conditions the APC-sr
was 13 for normal pooled plasma and 50 and 81 for heterozygous and
homozygous APC-resistant plasma, respectively.
Influence of Plasma Dilution on the APC-sr
To establish the range of plasma dilutions at which the APC resist-
ance test can be performed, we have determined the APC-sr as a func-
tion of the plasma dilution (Fig. 2). At low plasma dilutions the APC-sr
of the different plasmas approached the same value (-50). This may be
caused by effects of other plasma proteins (e.g. protein S, cf. ref. 35) on
the inactivation of factor Ya b1' APC or by underestimation f the
amount of factor Va present in the plasma sample. When too much fac-
tor Va is introduced in the factor Va assay mixture, factor Xa and pro-
thrombin become lirniting, which will cause an underestimation f the
factor Va concentration especially in the plasma sample that was not
treated u ith .\PC
Reliable difterences between the APC-sr of normal and APC-resist-
ant plasmar s ere obtained when the test was performed on plasma sam-
ples that u ere diluted 500 to 5000 times. At higher dilutions of the plas-
ma samples. the thrombin used t0 activate factor V in the plasma sam-
ple sigilicantly contributed to the thrombin determined in the factor
\-a a-isa)' Conection for this contribution (typically <5% in the absence
of -\PC. and 5 -25V0 in the presence of APC) required subtraction of an
:-;.a] blank in which plasma was substituted with buffer.
Test Results for a Population of Notmal Plasmas and Plasmas
from Heterozy gous or Homory gous AP C -resistant Individuals
Plasmas from a number of normal (n = 33), heterozygous (n = 17)
and homozygous individuals (n = 7), both men and women, were
screened using the method escribed in the previous paragraphs. For al1
plasmas the presence or absence of the factor VR506Q mutation was ve[-
ified by genetic analysis of genomic DNA samples. In agreement with
the results presented in previous paragraphs for the single plasmas,
clear differences were observed for the three different groups of plas-
mas (Fig. 3). The APC-sr values of the plasmas actually divided into
three populations: 12.3 t 0.38 (mean 1 SEM), for normal plasmas,
42.3 x 1.0 for the plasmas of heterozygous APC-resistant individuals
and 85.6 t 0.63 for the plasmas of homozygous APC-resistant i divid-
uals, The ranges of APC-sr observed for these three populations were
8-20, 35-50 and 82-88 respectively. There was no overlap between the
three groups of plasmas, i.e. the APC-sr of homozygous APC- resistant
individuals was significantly higher than the APC-sr of heterozygous
APC-resistant individuals (p <0.0001). A similar difference was ob-
served between the APC-sr of the plasma of heterozygous APC-resist-
ant individuals and the plasma of normal individuals. The outcome of
the chromogenic APC resistance t st was in full agreement with the
results obtained by DNA analysis.
The Chromogenic APC Resistance Test and Plasma
with C oa gul ati on Abnormal itie s
APC resistance t sts that are based on measurement of the effect of
APC on the APTT give less reliable results in plasmas with abnormal
APTT values e. g. in the case of coagulation factor deficiencies (17, 20,
21), anticoagulant treatment with heparin or oral anticoagulants (2,4, 6,
17, 23), the presence ofLupus anticoagulant (22), pregnancy (21) or the
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Fig.2 The influence of the plasma dilution on the response of the various
plasmas to APC The factor V present in varying dilutions of normal-pooled
plasma (l) or plasma from a heterozygous (O) or a homozygous APC-resist-
ant individual (A) was activated by incubating the plasma dilution during
10 min with 4 nM thrombin at 37" C Factor Va was further incubated for 6 min
with or without 0.2 nM APC in the presence of 21.7 pM phospholipid vesicles
(10/90 DOPS/DOPC MA4). The remaining cofactor activity of factor Va was
determined in a protlrombinase mixture containing 0.3 nM factor Xa, I pM
prothnombin and 20 pM phospholipid vesicles (10/90 DOPS/DOPC M/IVI). The
APC-sr (factor Va**./factor Va-org) was conected for an assay blank, deter-
mined with a reaction mixture that did not contain plasma. For practical
reasons, the APC-sr was multiplied by i00 in order to obtain integers. Further
exnerimental details are siven under Materials and Methods
Fig.3 Range of APC-sr of plasmas from healthy volunteers and heterozy-
gous and homozygous APC-resistant i dividuals The effect of APC on the co-
factor activity offactor Va generated in a 1/1000 dilution of the plasma samples
was determined as described in the Materials and Methods (cf. Fig. 2) The
plasma samples were classified as belonging to normal healthy individuals (O),
heterozygous APC-resistant individuals (O) or homozygous APC-resistant
individuals (O) by DNA analysis. The data obtained were plotted as APC-sr =
factor Va*on./factor Va-oo. multiplied by 100. Median values are indicated per
group. P-values are given. The position of the theoretical APC-sr (see Discus-
sion) is indicated per group of plasma samples (-+)
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Table I APC-sr for normal plasmas and plasmas with abnonnal coagulation
properties
APC-sf
Plasma from normal individuals
Heterozygous APC resistant plasma
Homozygous APC resistant plasm
Protein S deficient plaffi
Plasma (oral anti@gulatm)
Plasma (Hepain bedHt)
Plasma (tral qfi-mptim)
Plffi(pGgrsrcy)
Plffi (Lrpus anti@agulans)
41 9a1 0  35-50
8 6 0 t 0 6 3  8 2 € 8
'12 8 lO 70 12-14
15 4 !1  20  12-20
159!074 14-18
1 3 1 ! 0 4 9  1 0 - 1 8
1 2 6 f 0 6 1  1 2 - 1 4
1 2 0 r 0 9 6  1 0 - 1 4
1 2 3 1 0 3 8
1 7
7
8
0001
0001
o 8 0o
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fThe APC-sr for the different plasmas was determined as described in the legend of
Fb 2 M€an I S E M are given, n: number of different plasma samples tested
imnodepleted and plasma from a heterozygous protein S deficient patient (<5%
fre proiein S antigen)
use of oral contraceptives (24, 25). Since our test is performed on high-
ly diluted plasma samples it is only dependent on plasma factor V and
is not dependent on other plasma components. Hence, it is not surpris-
ing that for all "abnormal plasmas" tested the APC-sr values obtained
by our assay were within the range of normal plasmas (Table 1).
Modification of the Chromogenic APC Resistance Test
for Use on an Autoanalyzer
Although the test described above is rather easy to perform we have
adapted the assay for use on an ACL-300 Research Automated Coagu-
lation Apparatus. In this application the plasma dilution, the activation
of factor V and inactivation of factor Va were performed outside the
apparatus but the factor Va was determined on the autoanalyzer. It ap-
peared possible to activate plasma factor V and inactivate the factor Va
with APC in a single step by incubating the plasma dilution with 20 pM
phospholipids, 4 nM thrombin in the absence or presence of 0.4 nM
APC during 20 min. After this incubation the sample was diluted 12-
fold with cold Hepes buffer and stored on ice in order to block further
factor Va inactivation. The factor Va present in the plasma samples thus
obtained appeared to be stable for at least one hour, which allowed a
factor Va determination on the autoanalyzer. In the autoanalyzer the
treated plasma sample was mixed with a solution containing prothrom-
bin, factor Xa and phospholipid vesicles (t = 0 min) and subsequently
with a S2338/EDTA mrxture (t = 2 min) to stop prothrombin activation
and t0 determine tluombin. Under the chosen assay conditions the
thrombin formed was proportional to the amount of factor Va present in
the plasma sample. The results obtained with the semi-automated meth-
od are in good agreement with the data shown in Fig. 3 and also gave a
distinct APC-sr for the normal plasmas and the heterozygous and ho-
mozygous APC-resistant plasmas. The differences between the three
groups of plasmas tested were significant (p <0.0001). The APC-sr
408
Fig.4 Range of APC sensitivity ratios of plasmas from healthy volunteers
and heterozygous and homozygous APC-resistant individuals determined by a
semi-automated method. The APC-sr (factor Va*or./factor Va-or.) x 100 of
various plasmas was determined on an ACL-300 Research Automated Coagula-
tion apparatus as described in the Materials and Methods. The plasma samples
were classified as belonging to normal healthy individuals (O), heterozygous
APC-resistant i dividuals (O) or homozygous APC-resistant i dividuals (O)
by DNA analysis. Median values are indicated per group
(mean + SEM) for the three groups of plasmas tested were 12.2 t0.24,
45.3 x.0.72 and 11 .3 t 0.3 for the plasmas of normal, heterozy-
gous APC-resistant and homozygous APC-resistant i dividuals respec-
tively.
Discussion
In this paper we present a new functional test for the screening of
plasmas for APC resistance that is based on probing the effect of APC
on the cofactor activity of factor Va that is present in a thrombin-acti-
vated plasma sample. APC-catalyzed loss of cofactor activity of normal
factor Va is due to proteolytic leavage of peptide bonds located at
Args06 and A19306 of the heavy chain of factor Va (12-14). Factor Va
from APC-resistant i dividuals (factor VaRs06Q) is much slower inacti-
vated by APC (14) since it lacks the cleavage site at fug506.
In this paper we show that maximal differences in APC-mediated
loss of factor Va cofactor activities, present in thrombin-activated plas-
ma samples from normal individuals and heterozygous and homozy-
gous APC-resistant individuals, were obtained when 1) factor Va was
inactivated by APC in a high plasma dilution in the absence of factor
Xa and protein S and when 2) the factor Va cofactor activity was deter-
mined in a prothrombinase mixture containing alow factor Xa cohcen-
tration (Fig. 1).
This led to a rapid and simple method for the screening of plasmas
for APC resistance. Our procedure is based on comparison 0f the
amounts of factor Va cofactor activity present in thrombin-activated
plasma samples that were incubated uring 6 mrn with phospholipid
vesicles either in the absence 0r presence of 0.2 nM APC. The anti-
coagulant response of a given plasma sample to APC can be easily
quantitated from the so-called APC sensitivity ratio (APC-sr) which is
defined as the ratio of amounts of factor Va present in the APC-treated
and the non{reated plasma sample. The chosen reaction conditions al-
low full distinction between the normal plasmas and the plasmas from
individuals that were shown to be heterozygous or homozygous APC
resistant by DNA analysis (Fig. 3). This is in contrast t0 results obtained
with APTT-based APC-resistance assays, inwhich borderline zones for
the APC response are observed in which it is difficult to distinguish
normal, heterozygous and homozygous APC-resistant individuals (11,
15, 37) unless the plasma sample is diluted in factor V-deficient plasma
(38, 39) or buffer (40). The functional method for screening of APC re-
sistance described in this paper gives results that are fully compatible
with those obtained by DNA analysis. This is not surprising since the
determination is performed on highly diluted plasma samples which
makes the assay independent of other plasma components hat may af-
fect inactivation or quantitation of the factor Va present in the plasma
sampie, This has the additional advantage that our assay is not affected
by conditions that may interfere with coagulation-based t sts such as
coagulation factor abnormalities (20, 21), the presence of lupus antico-
agulants (22), anticoagtlant treatment (2,4,6,17 ,23), pregnancy (21)
or the use of oral contraceptives (24, 25) (Table l). A number of the het-
erozygote and homozygote APC-resistant i dividuals had been suffer-
ing from episodes of venous thromboembolism. In the prothrombinase-
based assay they were indistinguishable from healthy APC-resistant i -
dividuals.
It should be ernphasized that the actual value of the APC-sr is depen-
dent on reaction conditions uch as pH, temperature, the concentrations
of APC and phospholipid vesicles and the time of incubation with APC.
When the reaction conditions are not strictly controlled, different APC-
sr may be obtained. Day to day variation of the APC-sr can, however,
be minimized by predetermining the APC-sr of a normal pooled plasma
as a function of the incubation time with APC and taking in the actual
test an incubation time that yields an APC-sr of 10-15 in the pilot ex-
pgnment.
Actually, the APC-sr obtained in the experiment presented in Fig. 3
should equal a theoretical value that can be calculated using rate con-
stants for APC-catalyzed cleavage of the peptide bonds located at
A19506 and A19306 reported in an earlier paper from our group (14). Us-
ing rate constants of 6.7 X 10-5 s-1 for the spontaneous loss of factor Va
cofactor activity and 4.3 x 107 M-l s-l for APC-catalyzed cieavages at
Args06 and 2.3 x 106 M-1s-1 for cleavage at 419306 (i4), theoretical
APC-sr of 10, 46 and 85 are calculated for the plasma of normal indi-
viduals, heterozygous (assuming 50Vo normal factor V and 5070 factor
VR506a) nd homozygous APC-resistant individuals, respectively. The
theoretical values for the APC-sr closely approach the values experi-
mentally obtained (Fig. 3).
We have shown that it is possible t0 use an autoanalyzer in order to
increase the number of samples that can be tested simultaneously. In the
semi-automated method the activation of plasma factor V by thrombin
and the inactivation of factor Va by APC occur in a single step in a
37" C waterbath and the amount of factor Va present in the plasma sam-
ple is determined on an autoanalyzer by subsequently mixing the plas-
ma sample with prothrombinase components (phospholipids, Ca2* ions,
prothrombin and factor Xa) and with a solution containing the throm-
bin-specihc hromogenic substrate 52238 in EDTA (to block further
prothrombin activation). When the reaction conditions and the incuba-
tion times were chosen properly, the rate of 52238 conversion appeared
to be proportional with the amount of factor Va present in the plasma
sample and values for APC-sr allowed discrimination between ormal,
heterozygous and homozygous APC-resistant plasmas (Fig. a).
The combination of reiiability, reproducibility and easy perform-
ance, together with the fact that the assay is not disturbed in plasmas
with abnormal coagulation characteristics, make the APC-resistance
test that is presented in this paper an excellent method to screen plasma
samples for APC resistance. The test actually gives direct information
on the presence of Args06-+Gln mutation and gives distinct results with
normal, homozygous and heterozygous APC-resistant plasmas that are
fully compatible with those obtained with DNA-based assays. It is to
be expected that the test will also recognize other abnormalities related
to the factor V gene that can cause APC resistance ( .g. mutations or
variable xpression of factor V alleles in R506Q heterozygotes)
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Summory
In this paper we present anew method for the detection of resistance
to activated protein C (APC) that is based on direct measurement of the
effect of APC on the cofactor activity of plasma factor Va. The factor V
present in a diluted plasma sample was activated with thrombin and its
sensitivity towards APC was subsequently determined by incubation
with phospholipids and APC. The loss of factor Va cofactor activity
was quantified in a prothrombinase ystem containing purified pro-
thrombin, factor Xa and phospholipid vesicles and using a chromogen-
ic assay for quantitation ofthrombin formation. The reaction conditions
were optimized in order to distinguish normal, heterozygous and ho-
mozygous APC-resistant plasmas. Maximal differences in the response
of these plasmas towards APC were observed when factor Va was inac-
tivated by APC in the absence of protein S and when the cofactor activ-
ity of factor Va was determined at a low factor Xa concentration
f0.3 nM).
Addition of 0.2 nM APC and 20 pM phospholipid vesicles to a
1000-fold iluted sample of thrombin-activated normal plasma resulted
in loss of more than 857o of the cofactor activity factor Va within
6 min. Under the same conditions, APC inactivated -60V0 and -2070 of
the factor Va present in plasma samples from APC-resistant i dividuals
that were heterozygous or homozygous for the mutation fug506+Gln in
factor V, respectively. Discrimination between the plasma samples
from normal and heterozygous and homozygous APC-resistant i divid-
uals was facilitated by introduction of the so-called APC-sensitivity
ratio (APC-sr). The APC-sr was defined as the ratio of the factor Va co-
factor activities determined in thrombin-activated plasma samples after
6 min incubation with or without 0.2 nM APC and was multiplied by
100 to obtain integers (APC-sr = {factor Va**./factor Va-o..J x 100).
Clear differences were observed between the APC-sr of plasmas from
normal healthy volunteers (APC-sr: 8-20, n = 33) and from individuals
that were heterozygous (APC-sr: 35-50, n = 17) or homozygous APC
resistant (APC-sr: 82-88, n = 7). There was no mutual overlap between
the APC-sr of normal plasmas and plasmas from heterozygous or ho-
mozygous APC resistant individuals (p <0.0001). In all cases our test
gave the same result as the DNA-based assay. Since the test is per-
formed on a highly diluted plasma sample there is no interference by
conditions that affect APC resistance t sts that are based on clotting
time determinations (e. g. coagulation factor deficiencies, oral anticoag-
ulation, heparin treatment, he presence of lupus anticoagulants, preg-
Conespondence to:Dr. J. Rosing, Department of Biochemistry, Cardiovas-
cular Research Institute Maastricht (CARIM), University of Limburg, PO Box
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nancy or the use of oral contraceptives). Furthermore, we show that part
of the factor Va assay can be performed on an autoanalyzer which in-
creases the number of plasma samples that can be handled simultane-
ously,
Inlroducfion
In 1993, Dahlblick et al. (1) described a hereditary defect in the anti-
coagulant response to activated protein C (APC) that is associated with
an increased risk for venous thrombosis. This abnormality, called APC
resistance, was subsequently identified as the most cofilmon defect in
thromboembolic patients (2-6) and was found in20-50%0 of patients
with venous thrombosis. APC resistance is associated with familial
thrombophilia nd is inherited as an autosomal dominant trait. The mo-
lecular defect responsible for APC resistance isa single point mutation
in the gene encoding for coagulation factor V. This mutation results in
the substitution of Args06 by Gln in the heavy chain domain of factor
V(a) (7-1 l). Since 419506 constitutes one ofthree APC cleavage sites in
factor Va (12), the mutated factor V(a), also described as factor Vkid'n
or factor VR506Q, is much less effectively inactivated by APC than
normal factor Va (13, 14). Since APC-catalyzed inactivation of factor
Va is a crucial step in the down-regulation f thrombin formation this
likely explains the increased risk for venous thromboembolism in indi-
viduals with APC-resistant plasma.
The requirement for reliable detection of APC resistance became im-
portant when it was discovered that at least 2 to 470 ofthe Caucasian
population is APC-resistant (2, 3, 6, 7). Several methods for the diagno-
sis of APC resistance have been described so far (15). Most of these
methods are based on sequence analysis of genomic DNA (7, 16) or on
measurement of the effect of APC on the activated parlial thromboplas-
tin time (APTT) (1, 17, 18) 0r on thrombin generation i  plasma (19).
APTT-based APC-resistance assays appear to be less reliable in the
case of other coagulation disorders (11,20-22), anticoagulant therapy
(2,4,6,z3),pregnancy (21) or the use oforal contraceptives (24,25).
In this paper, we repofi a different method for the identification of
APC-resistant plasmas. The method is based on direct measurement of
the effect of APC on the activity of factor Va in diluted thrombin-acti-
vated plasma samples and subsequent detemination of factor Va cofac-
tor activity in prothrombin activation.
Moleriols ond Mefhods
Materials andBffirs
The phospholipids 1,2-dio1eoyl-sn-glycero-3-phosphoserine (DOPS) a d
1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) were obtained from Avanti
Polar Lipids, Alabaster, Alabama, USA. The chromogenic substrates D-Phe-
(pipecolyl)-Arg-pNA (S2238) and L-pyroGlu-Pro-Arg-pNA (S2366) were sup-
plied by Cluomogenix, Mtilndal, Sweden Recornbinant human ApC (rApC)
was a kind gift of Immuno AG, Vienna, Austria. Human protein S was
purchased from Enzyme Research Laboratories, Swansea, United Kingdom.
Human prothrombin and human factor X were purified as described by DiSci-
pio et al. (26). Human factor X was converted into factor Xa by incubation with
the purified factor X activator from Russel's viper venom and factor Xa was
isolated from the activation mixture by chomatography on soybean trypsin in-
hibitor-Sepharose (27).
All proteins used in the APC resistance t st were diluted in buffer I (25 mM
Hepes [pH 7.5], 175 mM NaCl, 3 mM CaCl, and 5 mg/ml BSA)
P ho spholipid V e sicle P reparations
Small unilamellar phospholipid vesrcles composed of a mrxture of DOpS/
DOPC (10/90, M/N4) were prepared as described earlier (28). phospholipid
concenftations were determined by phosphate analysis (29).
P rote in C o nc ent rations
APC concentrations were determined with 52366 using kinetic parameters
repofied by Sala et al (30). Thrombin concentrations were determined with the
chromogenic substrate 52238 (31) Protein S concentrations were calculated
from the Arro using an ArT"rro f 9.5 and Mr = 70,000 for protein S (32) Factor
V and factor Va concentrations were determined by measuring their activity in
prothrombin activation (14, 33) under conditions described in the legends to the
figures.
Collection and Handling of Plasma Samples
Nine parts of blood from normal healthy volunteers or from individuals
(both men and women) that were shown to be heterozygous orhomozygous for
the Arg506-+Gln mutation in factor V by DNA analysis (34) were collected in
one part of 0.13 M trisodium citrate (pH 7.8). The blood was centrifuged twice
for 15 minutes at 3,000 X g at room temperature The platelet poor plasma thus
obtained was stored at -80'C The healthy volunteers had a normal ApTT and
prothombin time, a normal response to APC and DNA analysis howed that
they were not canying the Arg506-+Gln mutation. A normal plasma pool was
obtained by mixing the plasma of 84 different healthy volunteers (borh men and
women). Coagulation factor concentrations (including protein S and C) of alt
volunteers were within the normal ranse
Chromo genic AP C -re sistanc e Test
The procedure that we have developed basically consists of tluee steps that
are performed at 31" C: 1) activation of plasma factor V with thrombin, 2) in-
cubation of factor Va with or without APC and 3) quantification of factor Va
cofactor activity.
Step 1: To two tubes (samples A and B) with 215 pl of 1/1000 dilutions of
the same plasma sample in buffer I, 5 pl of a mixture of 175 nM thrombin and
I mM phospholipid vesicles (10/90 MA4 DOPS/DOPC) were added ro acrivare
the factor V present in the plasma sample.
Step 2: After 10 min 10 p1 buffer I was added to sample A and 10 pl puri-
fied rAPC (4.6 nM) was added to sample B and the incubation at 37o C was
continued.
Step 3: After 6 min incubation with APC, 10 pl prothrombin (25 pM) and
10 pl factor Xa (7.5 nM) were added to the samples A and B in order to deter-
mine the factor Va cofactor activity present. After I min, the amount of tluom-
bin generated in the reaction aliquots was quantitated by transferring a 10 pl al-
iquot into a disposable cuvette with 990 pl of a buffer containing 235 pM 52238
in 50 mM Tris (pH '7.5 at 37" C), 175 mM NaCl, 0.5 mg/ml ovalbumin and
20 mM EDTA. The factor Va concentration i  the plasma sample was calculat-
ed from the thrombin formed using a calibration curve made with known
amounts of purified factor Va (34).
The final concentrations of essential reaction components in the different
steps were: step 1) 1/1000 dilution of plasma sample, 4 nM thrombin and
227 p"M DOPS/DOPC (10/90, MA4) vesicles; step 2), 0.2 nM APC and
21.7 p,M DOPS/DOPC (10/90) vesicles; step 3) 0.25 pM prorhrombin, 0.3 nM
factor Xa and 20 pM DOPS,DOPC (10/90) vesicles.
The tactor Va assay procedue (step 3) is essentially the same as reported
earlier (33). However, in this particular application factor Va was assayed at
0 3 nM factor Xa since at this factor Xa concentration the residual cofactor
activity of the reaction intermediate cleaved at Args06 is negligible compared
to native factor Va (14) This increased the difference in response between
normal and factor VaR506Q in the test (see Results) Plasma samples were
assayed within t h of thawing, although samples, kept at room temperature for
20 h, could be assayed without loss of assay accuracy. The intra-assay variation
of the test was 3% (n = I7), the inter-assay vari ationis 4Va (n = 20).
Semi-automated Method for the Detection of APC Resistance
Plasma samples were diluted 750 times in a 25 mM Hepes buffer (pH 7.5),
containing 175 mM NaCl, 5 mM CaCl, and 5 mg/ml BSA, (buffer II). After
prewarming two aliquots of 400 pl of the same plasma sample at 37" C, 16 pl
of a mixture of 67 nM thrombrn and 667 pM phospholipids (10/90 DOPS/
DOPC MA4) without (sample A) or with 10 nM APC (sample B) was added
yielding final concentrations of 4 nM thrombin, 20 pM phospholipid vesicles
with or without 0.39 nM APC, respectively. After 20 min incubation, i.e. acti-
vation of plasma factor V (sample A) or activation and inactivation of plasma
factor V (sample B) the reaction was stopped by the addition of 4500 pl cold
buffer I (4" C). After dilutron of the APCtreated plasma sample APC -catalyzed,
factor Va inactivation at 37o C is slowed down - 10O-fold and becomes consid-
erably slower than the rate of spontaneous loss of factor Va cofactor activity
(<0.3 Valminat37 " C). Since spontaneous loss offactor Va activity occurs both
in non{reated and APC-treated plasma samples any loss of factor Va activity
during the preincubation/incubation procedure in the ACL-300 will not affect
the APC-sr.
The cofactor activity of factor Va present in the plasma samples was deter-
mrned on an ACL-300 Research Automated Coagulation apparatus (Instrumen-
tation Laboratory, Milan, Italy). Prothrombin activation was started by mixing
50 pl aliquots of the plasma dilutions with 50 pl 2 p.M prothrombin, 0.6 nM
factor Xa and 40 pM phospholipids (10/90 DOPS/DOPC MA4) in 25 mM
Hepes (pH 7.5), 115 mM NaCl. After 2 min prothrombin activation was
stopped by mixing with 50 p.l of 60 mM EDTA in 25 mM Hepes (pH 7 5),
175 mM NaCl, 0.5 mg/ml ovalbumin and 2.35 mM 52238 and the thrombin
present was assayed by monitoring 52238 conversion for 1 min at 405 nm.
Under the conditions described above S2238 conversion appeared to be propor-
tional with the amount of factor Va present in the plasma sample
Statistics
Data are presented as ranges of values observed, median values or as mean
t S.E.M The Student's t-test was used to determine the significance of differ-
ences between test results of groups of plasmas.
Results
APC-mediated Inactivation of Factor Va Generated
in Normal-pooled Plasma nd in Plasmas from Heterozygous
and Homozy gous AP C -re sistant Indiv iduals
The chromogenic method to screen plasmas for APC resistance is
actually based on earlier publications from our $oup conceming asen-
sitive assay for factor Va (33), kinetic analysis of APC-catalyzed inac-
tivation of factor Va and factor VaR506Q ( 14) and the effects of protein S
and factor Xa thereon (35).
Recently, we have shown (14) that APC inactivates normal factor
Va 20 times faster than factor VaR506Q. The difference between the
observed rates of inactivation of factor Va and factor VaR506Q was
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Flg. 1 Effect of APC on the activity of factor Va generated in normal plasma
and in plasma from heterozygote and homozygote ApC-resistant individuals
Normal-pooled plasma (l), plasma from heterozygous (O) or homozygous(A) APC-resistant individual was diluted 1000 times in buffer I and factor V
was activated at 37" C with 4 nM thrombin the presence ofphospholipid ves_
icles (10/90 DOPS/DOPC M/[4) After 10 min ApC with or withour protein S
was added to inactivate factor Va. The formation and loss of factor Va cofactor
activity was followed as described in "Materials and Methods,,. For each plas_
ma sample the factor Va activity is given as Vo of its plateau value. Time
courses offactor V activation i  the different plasmas nd the spontaneous loss
of factor Va activity were indistinguishable andare therefore given in the
figure as a single averaged curve (O) for the tlilee different plasmas The final
concentrations f components during the inactivation and assay procedures
were: A) 0.2 nM APC and 21 7 pM phospholipid vesicles during inacrivation
and 0.3 nM factor Xa, I pM prorhrombin a d 20 pM phospholipid vesicles in
the factor Va assay mixture; B) 0.2 nM ApC, 200 nM protein S and 21 7 pM
phospholipid vesicles during inactivation and 0.3 nM factor Xa, 1 uM
prothrombin a d 20 pM phospholipid vesicles in the factor Va assay mixrure
and C) 0.2 nM APC and2l.1 pM phospholipid vesicles during inactivation a d
10 nM factor Xa, 1 pM prothrombin a d 20 pM phospholipid vesicles in the
factor Va assay mixture
maximal when the loss of cofactor activity of factor Va was monitored
in protlrombin activation mixtures that contained alow factor Xa con-
centration (e.g. 0.3 nM, cf. ref 14). Furthermore, we reported that dif_
ferences in the rates ofinactivation of factor Va and factor VaR506Q were
less pronounced oreven nuliified when factor Va was inactivated in the
presence of protein S and/or factor Xa (35).
Since the plasma of normal healthy volunteers contains - 25 nMfac-
tor V (36) and since our factor Va assay allows quantitation offactor Va
as low as 0.2 pM it is possible to determine the sensitivity of plasma
factor Va towards APC at high plasma dilutions (>1000-fold), indepen-
dent from and unaffected by other plasma cornponents. The procedure
that we have developed for distinguishing normal and ApC-resistant
plasmas basically consists of three steps: l) activation of the factor V
present in a highly diluted plasma sample with thrombin, 2) incubation
of factor Va in the presence of phospholipids with or without ApC and
3) quantification of factor Va cofactor activity. In order to obtain opti_
mal differentiation between plasmas from normal healthy individuals,
heterozygous and homozygous APC individuals the inactivation offac_
tor Va should theoretically be performed in the absence of factor Xa
and protein S (35) and the cofactor activity of factor Va should be as_
sayed at a low factor Xa concentration (14).
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Fig. 1A shows that under these conditions the factor Va formed by
thrombin in a normal plasma sample was indeed readily inactivated by
0.2 nM APC whereas the factor Va present in the plasma sample from
a heterozygous APC,resistant patient showed intermediate sensitivity
and that in plasma from a homozygous APC-resistant patient was very
slowly inactivated by APC. The differences in response towards ApC
were much less pronounced when protein S was present during factor
Va inactivation (Fig. 1B) or when the loss ofcofactor activity offactor
Va was assessed in a prothrombinase mixture that contained a high con-
centration of factor Xa (Fig. 1C).
For practical reasons it is preferable that an APC-resistance test is
based on measurement of sensitivity of plasma factor Va towards ApC
at a single time point. Quantitative comparison of the plasma samples
was facilitated by expressing their response towards ApC in terms of
the so-called APC sensitivity rario (APC-sr, cf . rcf .2,11, 17-1g). The
APC-sr is defined as the ratio of the factor Va activities determined af-
ter incubation of the plasma factor Va in the presence and absence of
APC and was multiplied by 100 to obtain integers (ApC-sr - {factor
Va*or./factor Va_o..] X 100). It appeared that under the reaction con-
ditions of the experiment presented in Fig. 1A, clear differences
between the APC-sr of the various plasmas were obtained for incuba-
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tion times between 2 and 15 min. Therefore, in the case of a single time
point assay, we have arbitrarily chosen for determination of the APC-sr
after 6 min incubation with APC. Under these conditions the APC-sr
was 13 for normal pooled plasma nd 50 and 81 for heterozygous and
homozygous APC-resistant plasma, respectively.
Influence of Plasma Dilution on the APC-sr
To establish the range of plasma dilutions at which the APC resist-
ance test can be performed, we have determined the APC-sr as a func-
tion of the plasma dilution (Fig. 2). At low plasma dilutions rhe APC-sr
of the different plasmas approached the same value (-50). This may be
caused by effects of other plasma proteins (e.g. protein S, cf. ref. 35) on
the inactivation of factor Va by APC or by underestimation f the
amount of factor Va present in the plasma sample. When too much fac-
tor Va is introduced in the factor Va assay mixture, factor Xa and pro-
thrombin become limiting, which wili cause an underestimation f the
factor Va concentration especially in the plasma sample that was not
treated with APC.
Reliable differences between the APC-sr of normal and APC-resist
ant plasmas were obtained when the test was performed on plasma sam-
ples that were diluted 500 to 5000 times. At higher dilutions of the plas-
ma samples, the thrombin used t0 activate factor V in the plasma sam-
ple significantly contributed to the thrombin determined in the factor
Va assay. Conection for this contribution (typically <5Vo inthe absence
of APC, and 5-257o in the presence of APC) required subtraction of an
assay blank in which plasma was substituted with buffer.
Test Results for a Population of Nomal Plasmas and Plasmas
from Heterozy gous or Homory gous AP C-re sistant Individuals
Plasmas from a number of normal (n = 33), heterozygous (n = 17)
and homozygous individuals (n = 7), both men and women, were
screened using the method escribed in the previous paragraphs. For all
plasmas the presence or absence of the factor VR506Q muta[on was ver-
ified by genetic analysis of genomic DNA samples. In agreement with
the results presented in previous paragraphs for the single plasmas,
clear differences were observed for the thnee different groups of plas-
mas (Fig. 3). The APC-sr values of the plasmas actually divided into
three populations: 12.3 t 0.38 (mean I SEM), for normal plasmas,
42.3 x 1.0 for the plasmas of heterozygous APC-resistant individuals
and 85.6 t 0.63 for the plasmas of homozygous APC-resistant i divid-
uals. The ranges of APC-sr observed for these three populations were
8-20, 35-50 and 82-88 respectively. There was no overlap between the
three groups of plasmas, i.e. the APC-sr of homozygous APC- resistant
individuals was significantly higher than the APC-sr of heterozygous
APC-resistant individuals (p <0.0001). A similar difference was ob-
served between the APC-sr of the plasma of heterozygous APC-resisf
ant individuals and the plasma of normal individuals. The outcome of
the chromogenic APC resistance t st was in full agreement with the
results obtained by DNA analysis.
The Chromogenic APC Resistance Test and Plasma
with C oa gul ati on Abnormal itie s
APC resistance t sts that are based on measurement of the effect of
APC on the APTT give less reliable results in plasmas with abnormal
APTT values e. g. in the case of coagulation factor deficiencies (17, 20,
2l), anticoagulant ffeatment with heparin or oral anticoagulants (2,4, 6,
17, 23), the presence ofLupus anticoagulant (22), pregnancy (21) or the
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Fig 2 The influence of the plasma dilution on the response of the various
plasmas to APC. The factor V present in varying dilutions of normal-pooled
plasma (I) or plasma from a heterozygous (O) or a homozygous APC-resist-
ant individual (A) was activated by rncubating the plasma dilution during
10 min with 4 nM thrombin at 37" C. Factor Va was further incubated for 6 min
with or without 0.2 nM APC in the presence of 21 7 pM phospholipid vesrcles
(10/90 DOPS/DOPC M/M) The remaining cofactor activity of factor Va was
determined in a protkombinase mixture containing 0.3 nM factor Xa, 1 pM
prothrombin and 20 pM phospholipid vesicles (10/90 DOPS/DOPC M/l\{). The
APC-sr (factor Va*or./factor Va_or.) was conected for an assay blank, deter-
mined with a reaction mixture that did not contain plasma. For practical
reasons, the APC-sr was multiplied by 100 in order to obtain integers. Further
experimental details are given under Materials and Methods
Flg. 3 Range of APC-sr of plasmas from healthy volunteers and heterozy-
gous and homozygous APC-resistant i dividuals. The effect of APC on the co-
factor activity of factor Va generated in a 1/1000 dilution of the plasma samples
was determined as described in the Materials and Methods (cf. Fig. 2). The
plasma samples were classified as belonging to normal healthy individuals (O),
heterozygous APC-resistant individuals (O ) or homozygous APC-resistant
individuals (O) by DNA analysis. The data obtained were plotted as APC-sr =
factor Va*o../factor Va_or. multiplied by 100. Median values are indicated per
group. P-values are given. The position of the theoretical APC-sr (see Discus-
sion) is indicated per group of plasma samples (-+)
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Table I APC-sr for normal plasmas and plasmas with abnormal coagulation
DrODerfles
APC-srF
o 8 0
o
FThe APC-sr for the different plasmas was determ ned as described in the legend of
F ig  2  Mean iS EM areg iven,  n  numbero f  d i f fe ren tpasma samples ies ted
immunodepleted and plasma from a heterozygous protern S deficient patient (<5%
free proiein S antigen)
use 0foral contraceptives (24,25). Since our test is performed on high-
ly diluted plasma samples it is only dependent 0n plasma factor V and
is not dependent on other plasma components, Hence, it is not surpris-
ing that for all "abnormal plasmas" tested the APC-sr values obtained
by our assay were within the range of normal plasmas (Table 1).
Modification of the Chromogenic APC Resistance Test
for Use on an Autoanalyzer
Although the test described above is rather easy to pertbrm we have
adapted the assay for use on an ACL-300 Research Automated Coagu-
lation Apparatus. In this application the plasma dilution, the activation
of factor V and inactivation of factor Va were performed outside the
appaiatus but the factor Va was determined on the autoanalyzer. It ap-
peared possible to activate plasma factor V and inactivate the factor Va
with APC in a single step by incubating the plasma dilution with 20 pM
phospholipids, 4 nM thrombin in the absence or presence of 0.4 nM
APC during 20 min. After this incubation the sample was diluted i2-
fold with cold Hepes buffer and stored on ice in order to block further
factor Va inactivation. The factor Va present in the plasma samples thus
obtained appeared to be stable for at least one hour, which allowed a
factor Va determination on the autoanalyzer. In the autoanalyzer the
treated plasma sample was mixed with a solution containing prothrom-
bin, factor Xa and phospholipid vesicles (t = 0 min) and subsequently
with a S2338/EDTA mixture (t = 2 min) to stop prothrombin activation
and to determine thrombin. Under the chosen assay conditions the
thrombin formed was proporlional to the amount of factor Va present in
the plasma sample. The results obtained with the semi-automated meth-
od are in good agreement with the data shown in Fig. 3 and also gave a
distinct APC-sr for the normal plasmas and the heterozygous and ho-
mozygous APC-resistant plasmas. The differences between the three
groups of plasmas tested were significant (p <0.0001). The APC-sr
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l-lg 4 Range of APC sensitivity ratios of plasmas from healthy volunteers
and heterozygous and homozygous APC-resistant i dividuals determined by a
semi-automated method The APC-sr (factor Va*or./factor Va-o..) X 100 of
various plasmas was determined on an ACL-300 Research Automated Coagula-
tion apparatus as described in the Materials and Methods. The plasma samples
were classified as belonging to normal healthy individuals (O), heterozygous
APC-resistant i dividuals (O) or homozygous APC-resistant i dividuals (O)
by DNA analysis. Median values are indicated per group
(mean + SEM) for the three groups of plasmas tested were 12.2 !0.24,
45.3 x 0.12 and ll .3 t 0.3 for the plasmas of normal, heterozy-
gous APC-resistant and homozygous APC-resistant i dividuals respec-
tively.
Discussion
In this paper we present a new functional test for the screening of
plasmas for APC resistance that is based on probing the effect of APC
on the cofactor activity of factor Va that is present in a thrombin-acti-
vated plasma sample. APC-catalyzed loss of cofactor activity of normal
factor Va is due to proteolytic leavage of peptide bonds located at
A19506 and Arg3oo f the heavy chain of factor Va (12-14). Factor Va
from APC-resistant i dividuals (factor VaR506a) is much slower inacti-
vated by APC (14) since it lacks the cleavage site at 419506.
In this paper we show that maximal differences in APC-mediated
loss of factor Va cofactor activities, present in thrombin-activated plas-
ma samples from normal individuals and heterozygous and homozy-
gous APC-resistant individuals, were obtained when 1) factor Va was
inactivated by APC in a high plasma dilution in the absence of factor
Xa and protein S and when 2) the factor Va cofactor activity was deter-
mined in a prothrombinase mixture containing alow factor Xa concen-
tration (Fig. l).
This 1ed to a rapid and simple method for the screening of plasmas
for APC resistance Our procedure is based on comparison of the
amounts of factor Va cofactor activity present in thrombin-activated
plasma samples that were incubated uring 6 mrn with phospholipid
vesicles either in the absence 0r presence of 0.2 nM APC. The anti-
coagulant response of a given plasma sample t0 APC can be easily
Plasma from normal individuals
Heterozygous APC resistant plasma
Homozygous APC resistant plasma
Protein S deficient plasma
Plasma (oral anticoagulation)
Plasma (Heparin treatment)
Plasma (oral contraception)
Plasma (pregnancy)
Plasma (Lupus anhcoagulans)
1 2 3 r 0 3 8  8 - 2 0
41 9r l  0  35-50
8 6 0 r 0 6 3  8 2 - 8 8
12 A lO 70  12-14
1 5  4  + 1  2 0  1 2 - 2 0
15 9  r :0  74  14-18
1 3 1 J 0 4 9  1 0 - 1 8
1 2 6 ! 0 6 1  1 2 - 1 4
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quantitated from the so-called APC sensitivity ratio (APC-sr) which is
defined as the ratio of amounts of factor Va present in the APC+reated
and the non{reated plasma sample. The chosen reaction conditions al-
low full distinction between the normal plasmas and the plasmas from
individuals that were shown to be heterozygous or homozygous APC
resistant by DNA analysis (Fig. 3). This is in contrast to results obtained
with APTT-based APC-resistance assays, inwhich borderline zones for
the APC response are observed in which it is difficult to distinguish
normal, heterozygous and homozygous APC-resistant i dividuals (11,
15, 37) unless the plasma sample is diluted in factor V-deficient piasma
(38, 39) or buffer (40). The functional method for screening of APC re-
sistance described in this paper gives results that are fully compatible
with those obtained by DNA analysis. This is not surprising since the
determination is performed on highly diluted plasma samples which
makes the assay independent of other plasma components that may af-
fect inactivation or quantitation of the factor Va present in the plasma
sample. This has the additional advantage that our assay is not affected
by conditions that may interfere with coagulation-based t sts such as
coagulation factor abnormalities (20, 21), the presence of lupus antico-
agulants (22), anticoagulant ffeatment (2, 4, 6, 17 ,23), pregnancy (21)
ortheuseof oralcontraceptives (24,25) (Table 1). Anumberof thehet-
erozygote and homozygote APC-resistant i dividuals had been suffer-
ing from episodes of venous thromboembolism. In the prothrombinase-
based assay they were indistinguishable from healthy APC-resistant i -
dividuals.
It should be emphasized that the actual value of the APC-sr is depen-
dent on reaction conditions uch as pH, temperature, the concentrations
of APC and phospholipid vesicles and the time of incubation with APC.
When the reaction conditions are not strictly controlied, different APC-
sr may be obtained. Day to day variation of the APC-sr can, however,
be minimized by predetermining the APC-sr of a normal pooled plasma
as a function of the incubation time with APC and taking in the actual
test an incubation time that yields an APC-sr of 10-15 in the pilot ex-
perlment.
Actually, the APC-sr obtained in the experiment presented in Fig. 3
should equal a theoretical value that can be calculated using rate con-
stants for APC-catalyzed cleavage of the peptide bonds located at
A19506 and A19306 reported in an earlier paper from our group (14). Us-
ing rate constants of 6.7 x 10r s-l for the spontaneous loss of factor Va
cofactor activity and 4.3 x 107 M-l s-r for APC-catalyzed cleavages at
A19506 and 2.3 x 106 M-1s-r for cleavage at A19306 (14), theoretical
APC-sr of 10, 46 and 85 are calculated for the plasma of normal indi-
viduals, heterozygous (assuming 50% normal factor V and 5070 factor
VRs06a) nd homozygous APC-resistant individuals, respectively. The
theoretical vaiues for the APC-sr closely approach the values experi-
mentally obtained (Fig. 3).
We have shown that it is possible [0 use an autoanalyzer in order to
increase the number of samples that can be tested simultaneously. In the
semi-automated method the activation of plasma factor V by thrombin
and the inactivation of factor Va by APC occur in a single step in a
37" C waterbath and the amount of factor Va present in the plasma sam-
ple is determined on an autoanalyzer by subsequently mixing the plas-
ma sample with prothrombinase components (phospholipids, Ca2'ions,
protlrombin and factor Xa) and with a solution containing the throm-
bin-specific hromogenic substrate 52238 in EDTA (to block further
prothrombin activation). When the reaction conditions and the incuba-
tion times were chosen properly, the rate of 52238 conversion appeared
to be proportional with the amount of factor Va present in the plasma
sample and vaiues for APC-sr allowed discrimination between ormal,
heterozygous and homozygous APC-resistant plasmas (Fig, 4)
The combination of reliability, reproducibility and easy perform-
ance, together with the fact that the assay is not disturbed in plasmas
with abnormal coagulation characteristics, make the APC-resistance
test thai is presented in this paper an excellent method to screen plasma
samples for APC resistance. The test actually gives direct information
on the presence ofArg506-+Gln mutation and gives distinct results with
normal, homozygous and heterozygous APC-resistant plasmas that are
fully compatible with those obtained with DNA-based assays' It is to
be expected that the test will also recognize other abnormalities related
to the factor V gene that can cause APC resistance ( .g. mutations or
variable xpression of factor V alleles in R506Q heterozygotes).
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